Pharmaceuticals
Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region
MELBOURNE, Australia, Nov. 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has signed an exclusive agreement withDenmark-based WIIK Pharma ApS (Wiik Pharma) for the distribution of Telix's investigational prostate cancer imaging agent, Illuc...
2023-11-08 13:00
1713
Docquity Expands Digitized Patient Access Programs To Enhance Healthcare Outcomes in Thailand
* After a successful pilot in the Philippines, five DocquityCare Patient Access Programs (PAPs)have been launched in Thailand * DocquityCare PAP will support more than 100 hospitals and 250 healthcare professionals (HCPs) to improve patient care for those with cancer and other life-threatenin...
2023-11-08 10:00
2350
WuXi Biologics Receives AAA MSCI ESG Rating
SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA rating from Morgan Stanley Capital International (MSCI) ESG Ratings, the highest rating for compan...
2023-11-08 08:30
1556
Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs
* During the event, Antengene will review promising data of its R&D pipeline, includingATG-031 (anti-CD24 monoclonal antibody), ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 antibody-drug conjugate), ATG-037 (CD73 inhibitor), and ATG-008 (dual mTORC1/2 inhibitor). * The vir...
2023-11-08 08:30
1904
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
* ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years. * ESR1 mutations are present in up to 40% of ER+, HER2- advance...
2023-11-08 02:01
1768
Recruitment target achieved for Phase II SAR-Bombesin prostate cancer trial
SYDNEY, Nov. 7, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that 50 patients have no...
2023-11-07 21:58
1379
Turn Biotechnologies First to Deliver mRNA into the Dermis Using Proprietary LNPs, With No Distribution to Other Organs
* Company's eTurna™ delivery platform ensures unprecedented precision, safety * In-vivo biodistribution of mRNA into dermal cells, tissues shows high transfection efficiency, gene expression * Data presented at ASDS Annual Meeting MOUNTAIN VIEW, Calif., Nov. 7, 2023 /PRNewswire/ -- Turn Biot...
2023-11-07 21:30
2724
Kexing Biopharm Attended CPHI Worldwide 2023
SHENZHEN, China, Nov. 7, 2023 /PRNewswire/ -- Recently, CPHI Worldwide 2023 was successfully held inBarcelona, Spain. Kexing Biopharm exhibited more than ten kinds of high-quality medical products in the fields of tumor, autoimmune, anti-virus, etc., including Infliximab, Adalimumab, Bevacizumab,...
2023-11-07 20:09
1543
Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)
HONG KONG, Nov. 7, 2023 /PRNewswire/ -- Akeso (9926.HK) announced positive results from an interim analysis of AK104-302 study, a randomized, double-blind, multicenter, phase III clinical study evaluating PD-1/CTLA-4 bispecific antibody, cadonilimab (开坦尼®) in combination with capecitabine plus...
2023-11-07 20:00
1949
BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel LIV-1 Targeting Antibody Drug Conjugate
SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the first patient has been dosed in the Phase I Clinical trial of BRY812, a third-generation antibody-drug conjugate (ADC) targeting LIV-1 for the treatment of advanced malign...
2023-11-07 14:14
1417
87.5% ORR | Abbisko presented two clinical updates of Pimicotinib at the 2023 CTOS Annual Meeting
SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) announced that two major clinical updates of its CSF-1R inhibitor pimicotinib（ABSK021）were presented at the 2023 Connective Tissue Oncology Society Annual Meeting, which is held inIreland from...
2023-11-07 12:31
1518
KN026 was Granted Breakthrough Therapy Designation by CDE
SUZHOU, China, Nov. 7, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced, that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) granted a Breakthrough Therapy d...
2023-11-07 08:51
1735
Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia
* A survey conducted in seven Asian markets, including Indonesia, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of respon...
2023-11-07 08:15
1201
Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia
* A survey conducted in seven Asian markets, including India, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of respondent...
2023-11-07 08:15
1090
Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia
* A survey conducted in seven Asian markets, including Vietnam, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of responde...
2023-11-07 08:15
1324
Unveiling the hidden struggles: Survey reveals worrying knowledge gap and emotional toll of infertility amidst record-low birth rates in Asia
* A survey conducted in seven Asian markets, including Taiwan, revealed that respondents, on average, spent 6.8 years on their fertility journey, with 3.6 years dedicated to trying to conceive naturally.1,2 * In Indonesia, Japan, Korea, Singapore, and Vietnam, at least 70 percent of responden...
2023-11-07 08:15
1220
Lerna Bio unveils its first-in-class solution to combat liver failure
SINGAPORE, CAMBRIDGE, Mass. and SHANGHAI, Nov. 6, 2023 /PRNewswire/ -- Lerna Biopharma Pte. Ltd (Lerna Bio) proudly announces the unveiling of its pioneering liver regeneration drug candidate, LR1, at The Liver Meeting inBoston organized by American Association for the Study of Liver Diseases (AA...
2023-11-06 22:00
1497
I-Mab Announces Participation at Jefferies and Piper Conferences in November
ROCKVILLE, Md. and SHANGHAI, China, Nov. 6, 2023 /PRNewswire/ -- I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies...
2023-11-06 21:00
1447
Phase I Study Results for Qilu Pharmaceutical's Iparomlimab (QL1604) Now Published
JINAN, China, Nov. 6, 2023 /PRNewswire/ -- Recently, the results of the Phase I study for iparomlimab (R&D code: QL1604), developed by Qilu Pharmaceutical Co., Ltd. were published online in the academic journalFrontiers in Immunology (2022 Impact Factor: 7.3). The title of the paper is "A first-i...
2023-11-06 18:54
1576
'Listen to your patients for early identification of Peripheral Neuropathy' say leading Health Experts at P&G's #KNOWTHESIGNS Scientific Forum
* 1 in 2 Diabetics and 1 in 10 Pre-diabetics estimated to suffer from PN * Vitamin B Deficiency affects quality of life of ~ 19% of all Diabetics * Unveil NEW NENOIN Study results on how B Vitamins improve sensory symptoms, motor function and motor strength in PN JAKARTA, Indonesia, Nov. 6, 2...
2023-11-06 17:07
1816
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 292 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 290 media titles]
2024-11-26 13:00Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9278
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7753
